graph EGM comparisons
atezolizumab alonetitlepembrolizumab alonetitledurvalumab alonetitleavelumab alonetitlenivolumab alonetitlepembrolizumab plus SoCtitleatezolizumab plus SoCtitleno additional treatmenttitlegemcitabine plus platintitleplacebo plus SoCtitleBSCtitleplacebotitleStandard of Care (SoC)titleIMvigor-010, 2021 NCT02450331 MIBC - NA - all population 406/403CheckMate 274 (all population), 2017 NCT02632409 MIBC - NA - all population 353/356CheckMate 274 (PDL1>1%), 2017 NCT02632409 MIBC - NA - PDL1 positive 140/142IMvigor-130 (At-arm B vs Ch-armC), 2020 NCT02807636 mUC - L1 - all population 360/400IMvigor-130 (At-arm A vs Pl-arm C), 2020 NCT02807636 mUC - L1 - all population 451/400DANUBE (D vs C - all population), 2020 NCT02516241 mUC - L1 - all population 346/344KEYNOTE-361 (P vs C), 2021 NCT02853305 mUC - L1 - all population 307/352KEYNOTE-361 (PC vs C), 2021 NCT02853305 mUC - L1 - all population 351/352DANUBE (D vs C - PDL1>25%), 2020 NCT02516241 mUC - L1 - PDL1 positive 209/207IMvigor-211 (all population), 2018 NCT02302807 mUC - L2 - all population 467/464KEYNOTE-045 (all population), 2017 NCT02256436 mUC - L2 - all population 270/272IMvigor-211 (PDL1>5%), 2018 NCT02302807 mUC - L2 - PDL1 positive 116/118IMvigor-211 (PDL1>1%), 2018 NCT02302807 mUC - L2 - PDL1 positive 316/309KEYNOTE-045 (PDL1 CPS >10%), 2017 NCT02256436 mUC - L2 - PDL1 positive 74/90JAVELIN Bladder 100 (all population), 2020 NCT02603432 mUC - M - all population 350/350JAVELIN Bladder 100 (PDL1>25%), 2020 NCT02603432 mUC - M - PDL1 positive 189/169

Pathology:  MIBC - NA - all population;   MIBC - NA - PDL1 positive;   mUC - L1 - all population;   mUC - L1 - PDL1 positive;   mUC - L2 - all population;   mUC - L2 - PDL1 positive;   mUC - M - all population;   mUC - M - PDL1 positive; 

MIBC - NA - all populationMIBC - NA - PDL1 positivemUC - L1 - all populationmUC - L1 - PDL1 positivemUC - L2 - all populationmUC - L2 - PDL1 positivemUC - M - all populationmUC - M - PDL1 positive
IMvigor-010, 2021CheckMate 274 (all population), 2017CheckMate 274 (PDL1>1%), 2017IMvigor-130 (At-arm B vs Ch-armC), 2020IMvigor-130 (At-arm A vs Pl-arm C), 2020DANUBE (D vs C - all population), 2020KEYNOTE-361 (P vs C), 2021KEYNOTE-361 (PC vs C), 2021DANUBE (D vs C - PDL1>25%), 2020IMvigor-211 (all population), 2018KEYNOTE-045 (all population), 2017IMvigor-211 (PDL1>5%), 2018IMvigor-211 (PDL1>1%), 2018KEYNOTE-045 (PDL1 CPS >10%), 2017JAVELIN Bladder 100 (all population), 2020JAVELIN Bladder 100 (PDL1>25%), 2020
atezolizumab alone5T1T1T1T1T1
pembrolizumab alone3T1T1T1
durvalumab alone2T1T1
avelumab alone2T1T1
nivolumab alone2T1T1
pembrolizumab plus SoC1T1
atezolizumab plus SoC1T1
no additional treatment0T0
gemcitabine plus platin0T0T0T0T0
placebo plus SoC0T0
BSC0T0T0
placebo0T0T0
Standard of Care (SoC)0T0T0T0T0T0T0